Royal Bank of Canada Grows Position in Haleon PLC Sponsored ADR $HLN

Royal Bank of Canada lifted its position in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 1.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,775,678 shares of the company's stock after acquiring an additional 42,063 shares during the quarter. Royal Bank of Canada owned approximately 0.06% of Haleon worth $28,561,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Bartlett & CO. Wealth Management LLC grew its stake in shares of Haleon by 135.9% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company's stock worth $27,000 after acquiring an additional 1,491 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of Haleon in the 1st quarter worth $29,000. Deutsche Bank AG grew its stake in shares of Haleon by 267.8% in the 1st quarter. Deutsche Bank AG now owns 3,126 shares of the company's stock worth $32,000 after acquiring an additional 2,276 shares in the last quarter. Continuum Advisory LLC grew its stake in shares of Haleon by 152.4% in the 1st quarter. Continuum Advisory LLC now owns 4,753 shares of the company's stock worth $49,000 after acquiring an additional 2,870 shares in the last quarter. Finally, Alpine Bank Wealth Management bought a new stake in shares of Haleon in the 1st quarter worth $56,000. Institutional investors own 6.67% of the company's stock.

Analyst Ratings Changes

HLN has been the subject of several recent analyst reports. Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. BNP Paribas Exane upgraded shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target for the company in a research report on Tuesday, May 27th. The Goldman Sachs Group upgraded shares of Haleon from a "neutral" rating to a "buy" rating in a research report on Wednesday. Finally, BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Haleon currently has an average rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Stock Performance

HLN traded down $0.07 during trading on Friday, hitting $9.81. 7,825,877 shares of the company traded hands, compared to its average volume of 7,793,643. The firm has a market cap of $43.91 billion, a P/E ratio of 25.14, a price-to-earnings-growth ratio of 2.91 and a beta of 0.24. The stock's fifty day moving average is $9.73 and its 200 day moving average is $10.20. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a one year low of $8.86 and a one year high of $11.42.

Haleon Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Thursday, September 18th. Shareholders of record on Friday, August 15th will be issued a dividend of $0.0555 per share. This represents a yield of 190.0%. This is a boost from Haleon's previous semi-annual dividend of $0.05. The ex-dividend date of this dividend is Friday, August 15th. Haleon's payout ratio is currently 28.21%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.